Loading…
Artivion, Inc. is projected to rise to $25.66 by 2027, a +7% move from its current price of $24.09. AORT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $23.49 | $24.10 | $24.73 | +0.03% |
| Jul 13 | $23.24 | $24.10 | $25.00 | +0.06% |
| Jul 14 | $23.06 | $24.11 | $25.21 | +0.09% |
| Jul 15 | $22.91 | $24.12 | $25.39 | +0.12% |
| Jul 16 | $22.78 | $24.13 | $25.56 | +0.15% |
| Jul 17 | $22.66 | $24.13 | $25.70 | +0.18% |
| Jul 18 | $22.55 | $24.14 | $25.84 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.55 | $24.14 | $25.84 | +0.21% |
| Week 2 | $21.97 | $24.19 | $26.64 | +0.43% |
| Week 3 | $21.55 | $24.24 | $27.28 | +0.64% |
| Week 4 | $21.20 | $24.30 | $27.84 | +0.86% |
| Week 5 | $20.91 | $24.35 | $28.35 | +1.07% |
| Week 6 | $20.65 | $24.40 | $28.83 | +1.29% |
| Week 7 | $20.42 | $24.45 | $29.28 | +1.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.
It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. It also offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities.
The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Artivion, Inc. is a healthcare company trading as AORT with a current price of $23.61 and a market capitalization of $1.15B. It ranks 2446 in market cap among peers. The price outlook from the provided forecast shows a path from a 2026 average of $23.61 to a 2050 average near $148.53, with yearly highs extending to $272.02 in 2050.
The trajectory suggests upside over the long term, though near-term momentum remains mixed.
A major floor 23.7% below — a decisive break under it would weaken the trend.
The nearest floor, 16.6% below — buyers have tended to step in here.
Price is pressing into resistance (2.4% away) — a breakout level to watch.
A major ceiling 61.1% above — clearing it would confirm fresh momentum.
Key AORT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AORT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.18 | Sell | $23.97 | Buy |
| MA 10 | $23.69 | Buy | $23.56 | Buy |
| MA 20 | $22.40 | Buy | $23.09 | Buy |
| MA 50 | $24.13 | Sell | $25.04 | Sell |
| MA 100 | $30.44 | Sell | $29.10 | Sell |
| MA 200 | $37.04 | Sell | $32.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.27 | Neutral |
| Stoch RSI (14) | 84.35 | Sell |
| CCI (20) | 85.61 | Neutral |
| Williams %R (14) | -12.58 | Info |
| MACD (12,26,9) | 0.45 | Buy |
| ROC (12) | 16.49 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 87.42 | Sell |
| TRIX (15) | -0.15 | Sell |
| Awesome (5,34) | 2.16 | Buy |
| Ultimate (7,14,28) | 67.25 | Neutral |
| Momentum (10) | 1.43 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 24.21 | Sell |
| ADX (14) | 20.62 | Buy |
| ATR (14) | 0.61 | Info |
The 30-day technical picture is neutral. RSI14 stands at 50, and the stock trades near its 50-day simple moving average of $26.84, well below its 200-day simple moving average of $37.90. Nearby resistance is at $23.76 and support sits at $20.10. The 30-day price range spans from $19.81 to $28.14, highlighting notable volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $20.10 | $24.09 | $31.74 | 0% | Neutral | |
| $20.54 | $25.66 | $33.86 | +7% | Neutral | |
| $20.92 | $26.83 | $36.66 | +11% | Neutral | |
| $24.13 | $31.62 | $44.41 | +31% | Bullish | |
| $26.79 | $35.78 | $51.44 | +49% | Bullish | |
| $30.29 | $41.16 | $60.39 | +71% | Bullish | |
| $31.54 | $43.57 | $65.09 | +81% | Bullish | |
| $29.48 | $41.34 | $62.78 | +72% | Bullish | |
| $31.68 | $45.07 | $69.50 | +87% | Bullish | |
| $34.68 | $50.02 | $78.22 | +108% | Bullish | |
| $45.34 | $69.58 | $115.43 | +189% | Bullish | |
| $88.61 | $151.18 | $273.48 | +528% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $20.10 | $24.09 | $28.80 | +0.00% |
| August 2026 | $21.06 | $24.82 | $30.01 | +3.02% |
| September 2026 | $20.88 | $24.77 | $30.27 | -0.20% |
| October 2026 | $20.31 | $24.23 | $29.88 | -2.16% |
| November 2026 | $20.56 | $24.65 | $30.62 | +1.72% |
| December 2026 | $21.08 | $25.39 | $31.74 | +2.98% |
Click any year to see its month-by-month AORT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The AORT price prediction for 2026 points to an average of $24.09 (low $20.10, high $31.74) — a potential gain of 0% on today's $24.09. A consolidation phase looks the most probable path here.
In 2027, AORT is projected to trade between $20.54 and $33.86, averaging $25.66 — a potential gain of +7% from today's $24.09. That is up +7% on the projected 2026 average. Price action looks broadly range-bound.
Artivion, Inc.'s 2028 outlook centres on $26.83, within a $20.92 to $36.66 range. That is up +5% on the projected 2027 average. That marks a +11% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, AORT could reach as high as $44.41, with a base case around $31.62 and support toward $24.13 — roughly +31% from $24.09. Momentum favours further upside here.
Expect AORT to range from $26.79 to $51.44 through 2030. The $35.78 average target implies a +49% move from current prices. That is up +13% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The AORT price prediction for 2031 points to an average of $41.16 (low $30.29, high $60.39) — a potential gain of +71% on today's $24.09. Momentum favours further upside here.
In 2032, AORT is projected to trade between $31.54 and $65.09, averaging $43.57 — a potential gain of +81% from today's $24.09. That is up +6% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Artivion, Inc.'s 2033 outlook centres on $41.34, within a $29.48 to $62.78 range. That is -5% versus the projected 2032 average. That marks a +72% change versus current levels. Momentum favours further upside here.
By 2034, AORT could reach as high as $69.50, with a base case around $45.07 and support toward $31.68 — roughly +87% from $24.09. Buyers look set to stay in control over this stretch.
Expect AORT to range from $34.68 to $78.22 through 2035. The $50.02 average target implies a +108% move from current prices. That is up +11% on the projected 2034 average. Momentum favours further upside here.
The AORT price prediction for 2040 points to an average of $69.58 (low $45.34, high $115.43) — a potential gain of +189% on today's $24.09. Buyers look set to stay in control over this stretch.
In 2050, AORT is projected to trade between $88.61 and $273.48, averaging $151.18 — a potential gain of +528% from today's $24.09. That is up +117% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in AORT today (≈ 41.511 AORT) could be worth
$6,275.77
+$5,275.77 (+528%) by 2050 · US Dollar
Based on the average projected AORT price of $151.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AORTwould be worth at today's price.
$1,000 invested in AORT on Jul 10, 2025 (≈ 30.712529 AORT) would be worth
$739.86
-$260.14 (-26.0%) today · 0.74× · US Dollar
Based on a AORT entry price of $32.56 vs. today's $24.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.97 | $1,005.01 | +0.5% |
| 1 month ago | $20.47 | $1,176.84 | +17.7% |
| 3 months ago | $37.63 | $640.18 | -36.0% |
| 6 months ago | $42.89 | $561.67 | -43.8% |
| 1 year ago | $32.56 | $739.86 | -26.0% |
| All time (5.0y) ago | $27.58 | $873.46 | -12.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AORT forecast.
Our base-case forecast reaches $48.00 around 2035.
Implied market cap at $48.00: $2.33B
Looking out over the multi-year horizon, the outlook turns increasingly bullish from the late-2020s onward. The 2029 forecast shows an average price of $31.03 with a 31.4% ROI and a bullish sentiment, rising to a 2030 average of $35.27 with a 49.4% ROI. By 2040, the forecast projects an average of $69.22 with a 193.2% ROI, and by 2050 an average of $148.53 with a 529.1% ROI.
Max forecast values accompany these averages: $51.07 in 2030, $116.07 in 2040, and $272.02 in 2050, all reflecting notable upside potential while acknowledging the uncertainty inherent in forward estimates. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
2030 min $26.24, avg $35.27, max $51.07; ROI 49.4%; sentiment BULLISH.
The forecast shows the average price rising from $23.61 in 2026 to $148.53 in 2050, with a max of $272.02 in 2050 and an overall ROI of 529.1% by 2050, though expectations are not guarantees and risks apply.
Yes, the 2040 max is $116.07 and the 2050 max is $272.02, indicating potential above $100 in the forecast across those years.
Current price is $23.61 and market cap is $1.15B.
30-day range low $19.81, high $28.14; annualized volatility 50%.
Artivion, Inc. Community Discussion
0Share your Artivion, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.